Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treatment pathway, healthcare resource utilization and direct cost of ALS in France: A nationwide claims database study.

Revue neurologique·2026

Same author

Limb Girdle Muscular Dystrophy Associated With TRIM32 Variants: A National Cohort Study.

Muscle & nerve·2026

Same author

Prevalence of SOD1 and C9orf72 Variants Among French ALS Population: The GENIALS Study.

European journal of neurology·2025

Same author

Improvement of apathy in early Parkinson's disease.

NPJ Parkinson's disease·2025

Same author

Congenital myasthenic syndromes by Epsilon subunit mutations: Phenotypic profiles of 17 Algerian families.

Revue neurologique·2024

Same author

Quantitative brainstem and spinal MRI in amyotrophic lateral sclerosis: implications for predicting noninvasive ventilation needs.

Journal of neurology·2023

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

Dehydroepiandrosterone for myotonic dystrophy type 1.

I Pénisson-Besnier¹, M Devillers, R Porcher

¹Centre de référence Maladies Neuromusculaires Nantes-Angers, Département de Neurologie, Centre Hospitalier Universitaire d'Angers, France.

|August 6, 2008

Summary

Dehydroepiandrosterone (DHEA) supplementation did not improve muscle strength in myotonic dystrophy type 1 patients. This 12-week trial found no significant benefits from either replacement or pharmacologic doses of DHEA.

More Related Videos

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

Related Experiment Videos

Last Updated: Jul 3, 2026

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

Area of Science:

Neurology
Endocrinology
Clinical Trials

Background:

Myotonic dystrophy type 1 (DM1) is potentially linked to reduced dehydroepiandrosterone (DHEA) levels.
Investigating DHEA's efficacy and safety in DM1 patients is crucial for potential therapeutic strategies.

Purpose of the Study:

To evaluate the effectiveness of oral dehydroepiandrosterone (DHEA) in improving muscle strength in patients with myotonic dystrophy type 1.
To assess the safety profile of DHEA treatment in this patient population.

Main Methods:

A prospective, multicenter, randomized, double-blind, placebo-controlled trial involving 75 ambulatory DM1 patients.
Participants received oral DHEA (100 mg/d or 400 mg/d) or placebo for 12 weeks.
Primary endpoint: change in Manual Muscle Testing (MMT) score; secondary endpoints included muscle function, respiratory/cardiac function, and quality of life.

Main Results:

No significant differences in MMT score changes were observed between DHEA groups (100 mg, 400 mg) and the placebo group at 12 weeks.
No statistically significant improvements were found in secondary outcome measures across all groups.
The study found no evidence of benefit for DHEA in improving muscle strength or other functional parameters in DM1 patients.

Conclusions:

A 12-week treatment with dehydroepiandrosterone (DHEA) at replacement or pharmacologic doses does not enhance muscle strength in ambulatory myotonic dystrophy type 1 patients.
Current evidence does not support the use of DHEA for improving muscle function in DM1.
Further research may be needed to explore other therapeutic avenues for DM1.